Today we provided an update on regulatory submissions for our investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 years and older. Moderna has filed for marketing authorization with the U.S. Food and Drug Administration, the European Medicines Agency, Health… pic.twitter.com/EQzOMTemq8
— Moderna (@moderna_tx) January 5, 2026
Moderna (MRNA) shares traded higher on Monday after the company announced the submission of multiple regulatory filings in countries, including the U.S., for marketing authorization of mRNA-1010, its messenger RNA-based seasonal influenza vaccine.